Obstructive sleep apnoea (OSA) and other sleep disordered breathing are common disorders causing significant morbidity, mortality and societal burden. A significant proportion of the patients are undiagnosed and consequently untreated. Due to the wide disease distribution we recommend increased disease awareness, especially among high-risk groups: patients with obesity, metabolic syndrome and cardio- and cerebrovascular diseases. Continuous positive airway pressure (CPAP) is the first-line of treatment together with weight reduction, whereas oral devices may be used for less severe OSA or in cases where CPAP cannot be used.